As a group will plan to review the current breast clinical trials portfolio, last month’s screening and accrual volumes, new study opportunities and on-going regulatory and compliance issues.  Protocol PIs, as part of their duty, are expected to attend this meeting in order to review their trials and account for any items of concern.